2020
DOI: 10.7326/m19-3773
|View full text |Cite
|
Sign up to set email alerts
|

Policy Recommendations to Promote Prescription Drug Competition: A Position Paper From the American College of Physicians

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
6
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(6 citation statements)
references
References 23 publications
0
6
0
Order By: Relevance
“…expensive choice, limiting the competitive benefit of 88 generics on the market [10]. Soaring advertisement spending may also divert financial resources away from pharmaceutical research and development [11].…”
Section: Introductionmentioning
confidence: 99%
See 4 more Smart Citations
“…expensive choice, limiting the competitive benefit of 88 generics on the market [10]. Soaring advertisement spending may also divert financial resources away from pharmaceutical research and development [11].…”
Section: Introductionmentioning
confidence: 99%
“…Although most advertising is regulated by the competition agency, the Federal Trade Commission, advertising of prescription drugs is regulated by the U.S. Food and Drug Administration (FDA) [1,11]. The FDA requires that drug advertisements convey a balanced disclosure of a medication's benefits and risks [10]. Pharmaceutical companies assert, however, that freedom of speech insulates them from many content restrictions, and the FDA to date has avoided wading into regulating anything beyond such disclosures [13].…”
Section: Introductionmentioning
confidence: 99%
See 3 more Smart Citations